Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Diazoxide choline extended-release tablets demonstrated favorable safety profile across 4 years among patients with Prader-Willi Syndrome.

Veligrotug demonstrated significant improvements in proptosis, diplopia, and clinical activity score among patients with active thyroid eye disease.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.